Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | MST1R dec exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| MST1R dec exp | bladder carcinoma | predicted - sensitive | Doxorubicin | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Adriamycin (doxirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202). | 26772202 | |
| MST1R dec exp | bladder carcinoma | predicted - sensitive | Epirubicin | Preclinical - Cell culture | Actionable | In a preclinical study, knockdown of MST1R (RON) increased sensitivity of a bladder carcinoma cell line to Ellence (epirubicin) under hypoxia in culture, resulting in decreased cell survival (PMID: 26772202). | 26772202 |